Compare Enphase Energy Inc (ENPH) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enphase Energy Inc vs Pfizer Inc — how do they compare? Enphase Energy Inc trades at $33.24 (market cap $4.43B), while Pfizer Inc trades at $27.78 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 36× Enphase Energy Inc's market cap, and Pfizer Inc pays a 6.14% dividend while Enphase Energy Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enphase Energy Inc for 72 Days and Pfizer Inc for 158 Days on average.
| ENPH | PFE | |
|---|---|---|
Market Cap | $4.43B | $159.59B |
Volume | 3,388,482 | 30,937,010 |
Sector | Energy | Health |
52-Week High | $72.33 | $29.02 |
52-Week Low | $26.12 | $23.67 |
Typical Hold Time | 72 Days | 158 Days |
Enterprise Value | $4.07B | $211.09B |
Dividend Yield | — | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENPH trades at $33.50, down 1.21% on the day, with a bearish technical signal and mixed earnings history. Revenue declined to $1.47B in 2025 from $2.3B in 2023, though net income margin improved to 11.68%. Recent news includes product approvals and manufacturing milestones for AI data centers, but the stock faces pressure from high borrowing costs impacting the solar sector. The company maintains solid liquidity with $1.62B in cash, but debt levels remain elevated.
The outlook is cautious; analyst consensus is a Buy with a $42.90 price target, but recent earnings misses and sector headwinds pose risks. Upside depends on execution in AI infrastructure and EV charging, while competition and interest rate sensitivity are key concerns. The stock offers potential for recovery if operational trends stabilize.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enphase Energy Inc
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
